1 citations
,
August 2024 in “British Journal of Dermatology” This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.
March 2025 in “Journal of Investigative Dermatology”